| editorial | Q871232 |
| scholarly article | Q13442814 |
| P50 | author | Joaquím Ruiz | Q43149456 |
| Jordi Vila | Q55030523 | ||
| P2093 | author name string | M Vargas | |
| J M Sierra | |||
| M M Navia | |||
| P2860 | cites work | The global epidemiology of resistance to ciprofloxacin and the changing nature of antibiotic resistance: a 10 year perspective | Q33606472 |
| Antimicrobial resistance of diarrheagenic Escherichia coli isolated from children under the age of 5 years from Ifakara, Tanzania. | Q33978363 | ||
| In vitro activity and fecal concentration of rifaximin after oral administration | Q33980321 | ||
| In vitro antibacterial activity of rifaximin against Clostridium difficile, Campylobacter jejunii and Yersinia spp. | Q34688414 | ||
| Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria | Q34722477 | ||
| Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative | Q34729751 | ||
| Rifaximin: a nonabsorbed antimicrobial in the therapy of travelers' diarrhea | Q34754721 | ||
| Etiology of traveller's diarrhea in Spanish travellers to developing countries | Q39018475 | ||
| Tropical and exotic infections. Proceedings of the 5th Liverpool Tropical School Bayer Symposium on Microbial Diseases. 14 February 1998. | Q50122839 | ||
| Antimicrobial Resistance of Nontyphoidal Salmonella Isolates in Traveler's Diarrhea | Q50144475 | ||
| Campylobacter jejuni as a cause of traveler's diarrhea: clinical features and antimicrobial susceptibility. | Q53351268 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | diarrhea | Q40878 |
| enteropathogen | Q63500873 | ||
| P577 | publication date | 2001-02-01 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | In vitro activity of rifaximin against enteropathogens producing traveler's diarrhea | |
| P478 | volume | 45 |
| Q34108534 | Bile acids improve the antimicrobial effect of rifaximin |
| Q37827877 | Biologic properties and clinical uses of rifaximin |
| Q38565000 | Effectiveness of rifaximin in prevention of diarrhoea in individuals travelling to south and southeast Asia: a randomised, double-blind, placebo-controlled, phase 3 trial. |
| Q46604531 | Effects of rifaximin on bacterial virulence mechanisms at supra- and sub-inhibitory concentrations |
| Q93380730 | Emergence of Resistance to Quinolones and β-Lactam Antibiotics in Enteroaggregative and Enterotoxigenic Escherichia coli Causing Traveler's Diarrhea |
| Q24605309 | Emerging Aeromonas species infections and their significance in public health |
| Q45088460 | Evaluation of Helicobacter pylori susceptibility to rifaximin |
| Q34987670 | Expert review of the evidence base for prevention of travelers' diarrhea |
| Q34987675 | Expert review of the evidence base for self-therapy of travelers' diarrhea |
| Q38682282 | Guidelines for the prevention and treatment of travelers' diarrhea: a graded expert panel report |
| Q44716101 | Prevention of travellers' diarrhoea: where and who? |
| Q35855732 | Review article: the antimicrobial effects of rifaximin on the gut microbiota |
| Q35090413 | Rifaximin for the treatment of acute infectious diarrhea |
| Q42792218 | Rifaximin for the treatment of hepatic encephalopathy. |
| Q36108487 | Rifaximin in the treatment of infectious diarrhea |
| Q34607677 | Rifaximin pharmacology and clinical implications |
| Q37704526 | Rifaximin therapy of irritable bowel syndrome |
| Q36140657 | Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections |
| Q37768415 | Rifaximin: a nonsystemic rifamycin antibiotic for gastrointestinal infections |
| Q36214684 | Rifaximin: a review of its use in the management of traveller's diarrhoea |
| Q38237218 | Rifaximin: beyond the traditional antibiotic activity |
| Q36416410 | Safety and tolerability of the antibacterial rifaximin in the treatment of travellers' diarrhoea |
| Q53781806 | The effect of sub-inhibitory concentrations of rifaximin on urease production and on other virulence factors expressed by Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa and Staphylococcus aureus. |
| Q37412963 | The role of rifaximin in the treatment and chemoprophylaxis of travelers' diarrhea |
Search more.